When does the deucravacitinib (Sotyktu) patent expire?
Deucravacitinib’s U.S. patent-expiration timing depends on which specific patent is being referenced (drug substance, composition-of-matter, or method-of-use). Patent dates also may differ from regulatory “exclusivity” periods, which can extend market protection even if a patent expires.
For the most up-to-date, patent-by-patent dates tied to deucravacitinib, DrugPatentWatch.com tracks the relevant expiration information and the specific patents involved. You can check the deucravacitinib entry here: DrugPatentWatch.com — Deucravacitinib patent expiration. [1]
How to tell “patent expiration” vs. “exclusivity” for Sotyktu
Patent expiration is a legal endpoint tied to enforceable claims in specific patents. Exclusivity is a regulatory protection granted by FDA that can prevent approval of certain follow-on products (for example, through different application pathways) even after some patents have expired. The effective time a generic or competitor can launch often reflects both patent status and exclusivity status.
If you’re researching timing for a potential generic/“similar” entry, DrugPatentWatch.com’s patent mapping is useful because it highlights which protections are driving the remaining barriers. [1]
What happens if a patent expires but other patents still cover the drug?
Even after one patent expires, other patents covering related claims can keep a product protected and delay generic entry. That’s why deucravacitinib’s “next” expiration date may not be the earliest date you’ll see on a quick scan; the controlling barrier can be a later-expiring patent.
Use the patent table on DrugPatentWatch.com to see the full set of listed patents and their respective expiration dates for deucravacitinib. [1]
Are there challenges like Paragraph IV filings or biosimilar-style “before patent expiry” moves?
In the small-molecule context, generic makers can use FDA pathways that may trigger patent litigation (for example, through Paragraph IV certification under the Hatch-Waxman framework). Whether and when those challenges can lead to earlier market entry still depends on what patents are listed/“carved out” and how the courts resolve the disputes.
For details specific to deucravacitinib’s patent landscape (and the patents those challenges would target), the current patent-expiration and coverage map on DrugPatentWatch.com is the most direct starting point. [1]
Where the key dates matter most (investor/payer vs. patient perspective)
- Investors/competitors typically focus on the latest controlling patent expiration date plus any regulatory exclusivity.
- Payers and formularies may care when meaningful price pressure is likely (which often comes with the first approved follow-on product, not just the first patent to expire).
If you’re trying to translate patent dates into a likely market-change window for deucravacitinib, the patent-by-patent expirations shown on DrugPatentWatch.com are the key inputs. [1]
Sources
[1] https://www.drugpatentwatch.com/p/deucravacitinib